Zymeworks Inc (ZYME) NPV

Sell:$14.39Buy:$14.40$0.37 (2.64%)

NASDAQ:2.20%
Market closed | Prices delayed by at least 15 minutes
Sell:$14.39
Buy:$14.40
Change:$0.37 (2.64%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$14.39
Buy:$14.40
Change:$0.37 (2.64%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Key people

Kenneth H. Galbraith
Chairman of the Board, President, Chief Executive Officer
Leone D. Patterson
Chief Financial Officer, Chief Business Officer, Executive Vice President
Jeffrey Smith
Executive Vice President and Chief Medical Officer
Paul A. Moore
Chief Scientific Officer
Susan M. Mahony
Lead Independent Director
Carlos E. Campoy
Independent Director
Alessandra Cesano
Independent Director
Troy M. Cox
Independent Director
Nancy Davidson
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US98985Y1082
  • Market cap
    $1.02bn
  • Employees
    294
  • Shares in issue
    68.88m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.